Centessa enters up to $200M loan with Oxford Finance, repays $110M Oberland debt

Centessa Pharmaceuticals plc

Initial $110M term loan funded; proceeds used to repay existing NPA with Oberland Capital in full.
Additional $40M available upon clinical milestone, $50M at lenders' sole discretion; maturity Dec 2029 or Dec 2030 if milestone met.
Interest rate floating at SOFR (floor 3.28%) + 5.00% margin; min 8.28%, max 10.50%.
Loan secured by substantially all assets including IP; minimum cash covenant begins Oct 2026, waived if market cap ≥$1B.
Termination of prior note purchase agreement with Oberland Capital dated Oct 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.